You just read:

REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

News provided by

REGENXBIO Inc.

Aug 27, 2019, 07:00 ET